Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Cavalleri Lab, |
RCV001171330 | SCV001328277 | uncertain significance | Chronic kidney disease | 2020-05-28 | criteria provided, single submitter | research | PP3, BS1 |
Invitae | RCV001859106 | SCV002165416 | uncertain significance | not provided | 2023-10-05 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 926 of the DSTYK protein (p.Asp926Tyr). This variant is present in population databases (rs148542303, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with DSTYK-related conditions. ClinVar contains an entry for this variant (Variation ID: 915849). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |